Cancer Biotherapy and Radiopharmaceuticals

SJR Rank #11,927H-index: 74SJR: 0.498Best quartile: Q2
Journal website: aims, scope and author guidelines
Publisher

Mary Ann Liebert Inc.

Country

United States

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Radiology, Nuclear Medicine and ImagingQ2
  • Medicine (miscellaneous)Q3
  • OncologyQ3
  • PharmacologyQ3
  • Cancer ResearchQ4

Areas: Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsMonoclonal and Polyclonal Antibodies ResearchCancer-related molecular mechanisms researchImmunotherapy and Immune ResponsesCircular RNAs in diseasesMicroRNA in disease regulationCancer Immunotherapy and BiomarkersNeuroendocrine Tumor Research AdvancesLymphoma Diagnosis and Treatment

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs065130195260

Documents per Year

202220250306090120

Detailed Information

ISSN

1084-9785, 1557-8852

SJR Best Quartile

Q2

Region

Northern America

Citations per Document (2 years)

1.94

References per Document

49.26

Coverage

1996-2026

Scope

Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Cancer Biotherapy and Radiopharmaceuticals coverage includes: Antibody drug conjugates Fusion toxins and immunotoxins Nanoparticle therapy Vascular therapy Inhibitors of proliferation signaling pathways.

Metrics from SCImago Journal Rank 2025. View on SCImago